Navigation Links
Accumetrics Appoints John J. Young, MD Chief Medical Officer
Date:11/11/2008

SAN DIEGO, Nov. 11 /PRNewswire/ -- Accumetrics, Inc. has announced the appointment of John J. Young, MD as Chief Medical Officer for the company. Dr. Young will serve in a part-time capacity in addition to his current appointment as Professor of Medicine and Director of the Cardiovascular Innovations Program at The Ohio State University in Columbus, Ohio. Dr. Young will serve as the main liaison to practicing clinicians, as well as coordinating ongoing research efforts and educational strategies.

"We are very pleased to welcome John to Accumetrics," said Timothy Still, President and CEO of The Company. "We look forward to leveraging his unique experience as a clinical investigator, as well as clinical expertise to continue to grow our Company."

Prior to joining The Ohio State University Medical Center, Dr. Young was the Co-Director of Cardiovascular Research & Education at the Swedish Heart & Vascular Institute in Seattle, Washington. Prior positions included Associate Director of the Lindner Center for Research & Education, and Director of Interventional Services at the Ohio Heart & Vascular Center, both in Cincinnati, Ohio. Dr. Young received his M.D. from The Ohio State University College of Medicine, where he completed both his Residency and Fellowship training. He also holds a Bachelor of Science degree in chemistry, with honors, from Wright State University, Dayton, OH. Finally, Dr. Young has received the distinction of being one of the "Best Doctors in America," and is a lifetime member of "Who's Who in Medicine & Healthcare."

About Accumetrics (http://www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow(R) System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

CONTACT:

Jules Abraham

Lippert/Heilshorn & Associates

212-838-3777

jabraham@lhai.com


'/>"/>
SOURCE Accumetrics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Timothy I. Still Appointed CEO at Accumetrics
2. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
3. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
4. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
5. NutraCea Appoints New Chief Financial Officer
6. Cardiac Science Appoints Dave Marver as Chief Operating Officer
7. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
8. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
9. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
10. Nikon Instruments Appoints LABSCO its Clinical Distributor in Six States
11. China Pharma Holdings, Inc. Appoints The Ruth Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
Breaking Biology Technology:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... 13, 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other ... identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on the ...
Breaking Biology News(10 mins):